Fig. 1.

Delta24-RGD therapy significantly increases numbers of intratumoral ICOS⁺ and PD-1⁺ CD3⁺ T cells. C57BL/6J mice were inoculated i.c. with 5 × 10⁴ GL261 cells and after 5 days treated i.c. with 2 × 10⁷ pfu Delta24-RGD and control mice were treated with 10 µL PBS. Mice were sacrificed after 24 h, 48 h, 72 h, 7 days, 9 days, and 14 days post-therapy and cells were processed for flow cytometry (n = 3–5 mice/time-point/group). (A) Delta24-RGD significantly increases intratumoral CD3⁺ T cells on day 14 after therapy, reflecting an increase in CD8⁺ T cells. (B) Absolute numbers of CD3⁺ T cells were assessed and the expression of each co-signaling receptor within CD3⁺ T cells is analyzed. On day 14 after Delta24-RGD therapy, there was an increase in ICOS⁺ and PD-1⁺ TILs. P values were calculated with the Student t-test, *P < .05.